Flossbach Von Storch SE trimmed its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 1.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,672,425 shares of the healthcare product maker's stock after selling 86,048 shares during the period. Abbott Laboratories accounts for 3.9% of Flossbach Von Storch SE's holdings, making the stock its 6th biggest position. Flossbach Von Storch SE owned about 0.50% of Abbott Laboratories worth $980,938,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also modified their holdings of ABT. Allspring Global Investments Holdings LLC boosted its stake in shares of Abbott Laboratories by 17.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 268,538 shares of the healthcare product maker's stock worth $30,616,000 after acquiring an additional 40,783 shares during the last quarter. Trilogy Capital Inc. boosted its stake in Abbott Laboratories by 5.6% during the 3rd quarter. Trilogy Capital Inc. now owns 2,503 shares of the healthcare product maker's stock worth $285,000 after purchasing an additional 132 shares during the last quarter. Copeland Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the third quarter worth $142,000. My Legacy Advisors LLC raised its position in shares of Abbott Laboratories by 2.3% in the third quarter. My Legacy Advisors LLC now owns 4,180 shares of the healthcare product maker's stock valued at $477,000 after buying an additional 92 shares during the last quarter. Finally, Symphony Financial Ltd. Co. lifted its stake in shares of Abbott Laboratories by 11.2% in the third quarter. Symphony Financial Ltd. Co. now owns 8,571 shares of the healthcare product maker's stock worth $964,000 after buying an additional 863 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.
Insider Activity
In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the completion of the transaction, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. The trade was a 15.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.10% of the company's stock.
Abbott Laboratories Trading Up 1.4 %
Shares of NYSE ABT traded up $1.87 during trading on Friday, reaching $135.04. The stock had a trading volume of 4,748,058 shares, compared to its average volume of 6,509,540. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The company has a market cap of $234.22 billion, a P/E ratio of 17.65, a PEG ratio of 2.46 and a beta of 0.75. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $135.41. The business's 50-day moving average price is $120.32 and its 200-day moving average price is $116.65.
Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.97 billion for the quarter, compared to analyst estimates of $11.03 billion. During the same period in the prior year, the firm earned $1.19 earnings per share. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. On average, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.
Abbott Laboratories Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.75%. Abbott Laboratories's dividend payout ratio (DPR) is 30.85%.
Analyst Ratings Changes
A number of research firms have commented on ABT. Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a report on Tuesday, January 28th. UBS Group lifted their price objective on Abbott Laboratories from $146.00 to $148.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Stifel Nicolaus upped their target price on Abbott Laboratories from $130.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. Royal Bank of Canada reiterated an "outperform" rating and set a $135.00 price target on shares of Abbott Laboratories in a report on Tuesday, January 21st. Finally, Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an "overweight" rating in a report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $133.06.
View Our Latest Stock Report on ABT
About Abbott Laboratories
(
Free Report)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Further Reading
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
